Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage iii non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 5, 2011, Pages 927-933

  Gadgeel, Shirish M ^a   Ruckdeschel, John C ^a   Patel, Bhaumik B ^b   Wozniak, Antoinette ^a   Konski, Andre ^a   Valdivieso, Manuel ^a   Hackstock, Deborah ^a   Chen, Wei ^a   Belzer, Kimberly ^a   Burger, Angelika M ^b   Marquette, Lauren ^b   Turrisi, Andrew ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

Concurrent therapy; NSCLC; Pemetrexed

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; PEMETREXED; THYMIDYLATE SYNTHASE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOGLYCEMIA; HYPONATREMIA; INFECTION; KIDNEY FAILURE; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PARTIAL BODY RADIATION; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIATION DOSE;

EID: 79955469120     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182156109     Document Type: Article

References (33)

1. van Meerbeeck JP, Surmont VF. Stage IIIA-N2 NSCLC: a review of its treatment approaches and future developments. Lung Cancer 2009;65: 257-267.
2. Jett JR, Schild SE, Keith RL, et al. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(Suppl 3):266S-276S. (Pubitemid 47502812)
3. Divers SG, Spencer SA, Carey D, et al. Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced nonsmall- cell lung cancer. J Clin Oncol 2005;23:6664-6673. (Pubitemid 46190261)
4. Blackstock AW, Lesser GJ, Fletcher-Steede J, et al. Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2001;51:1281-1289. (Pubitemid 33116322)
5. Vokes EE, Herndon JE II, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698-1704. (Pubitemid 46797950)
6. Gandara DR, Chansky K, Albain KS, et al. Long-term survival with concurrent chemoradiation therapy followed by consolidation docetaxel in stage IIIB non-small-cell lung cancer: a phase II Southwest Oncology Group Study (S9504). Clin Lung Cancer 2006;8:116-121. (Pubitemid 44596753)
7. Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent. Clin Cancer Res 2004;10:4276s- 4280s. (Pubitemid 38812462)
8. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597. (Pubitemid 41079796)
9. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy- naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-3551.
10. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
11. Seiwert TY, Connell PP, Mauer AM, et al. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res 2007;13:515-522. (Pubitemid 46225357)
12. Mountain CF. Staging classification of lung cancer. A critical evaluation. Clin Chest Med 2002;23:103-121. (Pubitemid 34207765)
13. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-991. (Pubitemid 44343542)
14. Smith V, Wirth GJ, Fiebig HH, et al. Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents. Cancer Genomics Proteomics 2008;5:263-273.
15. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21: 2636-2644. (Pubitemid 46606305)
16. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008;26: 2457-2463.
17. Govindan R, Bogart J, Wang X, et al. A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407-early evaluation of feasibility and toxicity. J Clin Oncol 2008; 26(Suppl 15):7518 (meeting abstracts).
18. Brade AM, Bezjak A, MacRae RM, et al. A phase II study of concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage IIIA/b nonsmall cell lung cancer (NSCLC). J Clin Oncol 2010;28(Suppl 15):7087 (meeting abstracts).
19. Choy H, Schwartzberg LS, Dakhil SR, et al. Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorableprognosis inoperable stage IIIA/b non-small cell lung cancer: interim update. J Clin Oncol 2010;28(Suppl 15):7082 (meeting abstracts).
20. Ma S, Xu Y, Ji Y, et al. Concomitant pemetrexed/carboplatin chemotherapy and 3D conformal radiotherapy followed by pemetrexed/carboplatin consolidation chemotherapy for locally advanced non-small cell lung cancer: preliminary results of a phase II study. J Clin Oncol 2010;28(Suppl 15):7092 (meeting abstracts).
21. Mornex F, Tourani JM, Wautot V, et al. Pemetrexed and cisplatin in combination with high dose of thoracic radiation, after induction chemotherapy, in patients with locally advanced non-small cell lung cancer: a phase I study. J Thorac Oncol 2010;5(S1):184O (abstract).
22. Hirsh V, Soulieres D, Duclos M, et al. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer. J Thorac Oncol 2007; 2:927-932. (Pubitemid 47511596)
23. Socinski MA, Morris DE, Halle JS, et al. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a doseescalation phase I trial. J Clin Oncol 2004;22:4341-4350. (Pubitemid 41185154)
24. Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000;343:254-261. (Pubitemid 30490393)
25. Ung YC, Maziak DE, Vanderveen JA, et al. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst 2007;99:1753-1767. (Pubitemid 351767209)
26. Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003;126:1943-1951. (Pubitemid 38020756)
27. Rodrigues G, Lock M, D'Souza D, et al. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer-a systematic review. Radiother Oncol 2004;71:127-138. (Pubitemid 38521180)
28. Madani I, De Ruyck K, Goeminne H, et al. Predicting risk of radiationinduced lung injury. J Thorac Oncol 2007;2:864-874. (Pubitemid 47361031)
29. Gaspar LE. Patient demographics in HOG LUN 01-24 versus SWOG 9504: apples versus oranges? Clin Lung Cancer 2007;8:466-467. (Pubitemid 47606354)
30. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008;26:5755-5560.
31. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006;107:1589-1596. (Pubitemid 44546920)
32. Simon GR, Ismail-Khan R, Bepler G. Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 2007;39:1318-1328. (Pubitemid 47031049)
33. Vokes EE, Senan S, Treat JA, et al. PROCLAIM: a phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 2009;10:193-198.